|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.0000 - 0.0000|
|52 Week Range|
|Beta (3Y Monthly)||5.29|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
Enhanced anti-tumor activity, improved overall survival, and an exponential increase in CAR-T cell proliferation was observed with GM-CSF neutralizationLenzilumab (an.
Humanigen, Inc., (HGEN) (“Humanigen”), a biopharmaceutical company developing its portfolio of Humaneered® monoclonal antibodies focused on CAR-T optimization and immuno-oncology announced that new research was published in the December issue of the journal Cancers demonstrating that the EphA3 receptor, the novel target for the company’s proprietary monoclonal antibody ifabotuzumab, is an attractive tumor-specific target for glioblastoma multiforme (GBM) therapy.
Humanigen, Inc., (HGEN) (“Humanigen”), a biopharmaceutical company focused on the development of its proprietary Humaneered® monoclonal antibodies to improve the safety and efficacy of chimeric antigen receptor T cell (CAR-T) therapy, announced that final results from the xenograft study of lenzilumab, a first-in-class anti-GM-CSF monoclonal antibody, were presented in the oral plenary session at the 2018 Annual Meeting of the American Society of Hematology, on Monday, December 3rd, 2018 by Rosalie Sterner from Mayo Clinic. The principal investigator for the study was Saad Kenderian, M.B., Ch.B., Mayo Clinic hematologist. The abstract entitled “GM-CSF Blockade during Chimeric Antigen Receptor T Cell Therapy Reduces Cytokine Release Syndrome and Neurotoxicity and May Enhance Their Effector Functions” was published as a first edition paper by ‘blood’® in the November 21, 2018 edition and is available online at http://www.bloodjournal.org/content/early/2018/11/21/blood-2018-10-881722. The full abstract with corresponding figures is available for review at: https://ash.confex.com/ash/2018/webprogram/Paper111766.html.
DALLAS , May 22, 2018 /PRNewswire/ -- Lupagen, Inc. ( www.lupagen.com ), a medical device company developing first-in-class cell and gene therapy delivery technologies for CAR-T, gene editing and immunotherapy ...